Thrombolysis in Factor Xa-inhibitors Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-14

Study Completion Date

2037-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study looks at whether stroke patients who take FXa inhibitors (a type of blood thinner) can safely receive clot-busting treatment (IVT). IVT is a common emergency treatment for stroke, but current guidelines say it should not be given to people who have taken FXa inhibitors in the last 48 hours. This is because doctors worry that IVT might cause dangerous bleeding in the brain.

However, new research suggests that IVT might be safe for these patients. Some studies even show that stroke patients on FXa inhibitors who receive IVT do not have a higher risk of brain bleeding than other stroke patients. But because these studies were not designed as full medical trials, doctors still avoid IVT for this group.

The SIFT trial will compare two groups of stroke patients who take FXa inhibitors:

One group will receive IVT to see if it helps them recover better. One group will not receive IVT, which is the current standard. Doctors will check if IVT helps with recovery and if it causes any serious bleeding. If IVT is found to be safe and effective, this study could change stroke treatment guidelines and help more patients get life-saving care.

Right now, some guidelines say that stroke patients on FXa inhibitors should have a blood test before getting IVT, to measure how much of the drug is in their system. But these tests are not available in most hospitals, and waiting for results could delay important treatment. The SIFT trial will not require this test before giving IVT.

More and more people use FXa inhibitors to prevent strokes, but right now, they are being denied IVT based on old rules. If this study proves that IVT is safe for them, it could help doctors give better care to thousands of stroke patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months

NCT06841978

Stroke Acute Ischemic Stroke

NOT_YET_RECRUITING PHASE3

Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke

NCT04818944

Acute Ischemic Stroke Ischemic Stroke

WITHDRAWN PHASE1/PHASE2

Endovascular Thrombectomy With and Without Intravenous Thrombolysis in Extended Time Window

NCT05634382

Stroke, Acute Ischemic

UNKNOWN PHASE3

Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic

NCT05415150

Acute Ischemic Stroke

UNKNOWN PHASE1/PHASE2

Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke

NCT07290751

Acute Ischemic Stroke

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The SIFT trial is a pragmatic phase III, multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE), registry-linked trial. It is designed to test the hypothesis that intravenous thrombolysis (IVT) is both safe and effective in patients with acute ischemic stroke (AIS) who have ingested a Factor Xa (FXa) inhibitor within the last 48 hours and are otherwise eligible for IVT. The study aims to address the current limitations in stroke guidelines, which recommend against IVT in these patients due to concerns of symptomatic intracranial hemorrhage (sICH). However, these recommendations are based on data from vitamin K antagonist (VKA) studies rather than direct evidence from randomized clinical trials (RCTs) involving FXa inhibitors. Observational data suggest that IVT in patients on FXa inhibitors is safe and effective, but a well-monitored RCT is necessary to confirm these findings.

All treatment and monitoring routines in the study follow hospital standard operating procedures (SOPs), and both alteplase (ALP) and tenecteplase (TNK) are approved drugs for AIS, with similar efficacy and safety profiles. IVT is known to be an effective treatment for disabling AIS, improving functional outcomes when administered within 4.5 hours of symptom onset. FXa inhibitors have largely replaced warfarin due to their better safety profile, reducing the risk of hemorrhagic complications by 50% compared to VKAs. The concern over sICH remains a major reason why patients on FXa inhibitors are often excluded from IVT, yet research suggests that the net benefit of IVT outweighs the risks, even with an sICH rate of up to 8%.

The primary objective of the study is to compare early neurological improvement (ENI) in patients treated with IVT versus those receiving standard care. Secondary objectives include assessing clinical neurological improvement, infarct volume changes on imaging, functional outcomes, rates of sICH, any intracranial hemorrhage (ICH) after IVT, and overall mortality. The study has a planned recruitment of 300 patients, with a 2:1 allocation favoring IVT. The sample size is designed to provide sufficient power for primary and secondary analyses, including the safety assessment of sICH rates. The study will be conducted across emergency departments and acute stroke units in Norway.

Eligibility criteria include patients aged 18 or older who have ingested an FXa inhibitor within 48 hours before symptom onset (or have an ongoing prescription if the exact timing of last ingestion is unknown). Patients must have a clinical diagnosis of AIS with disabling neurological deficits and present within 4.5 hours of symptom onset or after awakening with symptoms, confirmed by imaging. Informed consent is required. Patients with contraindications to alteplase or tenecteplase, those planned for endovascular treatment due to isolated large vessel occlusion (LVO) in the internal carotid artery (ICA) or middle cerebral artery (MCA) with expected rapid intervention, those using dabigatran, or those deemed at high risk by their treating physician are excluded.

Participants randomized to the IVT arm will receive either alteplase (0.9 mg/kg with a 10% bolus and 90% infusion over 60 minutes) or tenecteplase (0.25 mg/kg single bolus) according to local SOPs. The control group will receive 300 mg of aspirin and no IVT, in line with current practice guidelines. The study duration is planned from 2025 to 2029, with termination by December 2030 unless safety concerns necessitate earlier closure. The estimated duration of patient follow-up is 90 days.

The study follows an open-label, blinded-endpoint design, with patient randomization handled via a computerized system (Viedoc). Randomization is stratified by age and baseline NIH Stroke Scale (NIHSS) score. The primary outcome measure is early neurological improvement, defined as an NIHSS reduction of ≥8 points or an NIHSS score of 0-1 at 24 hours. Secondary outcomes include percentage change in NIHSS from baseline, infarct volume at 24 hours, functional outcomes at 90 days, and the incidence of sICH and any ICH within 36 hours. Death within 90 days is also assessed.

The primary analysis will use a logistic regression model, adjusting for age, NIHSS score, and time to treatment. Safety monitoring will be continuous, with an early stopping mechanism in place if the sICH rate in the IVT arm is deemed unacceptably high. The study's impact could be substantial; if IVT is proven safe and effective in AIS patients on FXa inhibitors, it would significantly influence stroke management, enabling more patients to receive IVT and reducing post-stroke disability. These findings would contribute to international discussions and could lead to guideline changes worldwide, allowing all IVT-capable centers to offer immediate, effective treatment to a growing patient population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Stroke (in Patients With Atrial Fibrillation) Ischemic Stroke Acute Ischemic Stroke Anticoagulant Therapy Factor Xa Inhibitor Intracranial Hemorrhages Hemorrhagic Transformation Due to Acute Stroke Bleeding in the Brain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A pragmatic phase III, multicenter, prospective, randomized, open label, blinded endpoint (PROBE), registry-linked, trial.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IVT

Intravenous Thrombolysis (IVT) with Alteplase or Tenecteplase

Group Type ACTIVE_COMPARATOR

thrombolysis therapy

Intervention Type DRUG

All treatment and monitoring routines are according to the hospitals' standard operating procedures (SOP), and both drugs (Alteplase (ALP) and Tenecteplase (TNK)) are approved drugs for the indication AIS with similar efficacy and safety profile. SIFT is designed to test the hypothesis that intravenous thrombolysis (IVT) (tenecteplase 0.25 mg/kg or alteplase 0.9 mg/kg intravenously) is efficient and safe in acute ischemic stroke patients (AIS) with recent ingestion (last 48 hours) of an Factor Xa (FXa) inhibitor who otherwise are eligible for IVT.

NO IVT

Standard Care Without Thrombolysis

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

thrombolysis therapy

All treatment and monitoring routines are according to the hospitals' standard operating procedures (SOP), and both drugs (Alteplase (ALP) and Tenecteplase (TNK)) are approved drugs for the indication AIS with similar efficacy and safety profile. SIFT is designed to test the hypothesis that intravenous thrombolysis (IVT) (tenecteplase 0.25 mg/kg or alteplase 0.9 mg/kg intravenously) is efficient and safe in acute ischemic stroke patients (AIS) with recent ingestion (last 48 hours) of an Factor Xa (FXa) inhibitor who otherwise are eligible for IVT.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Alteplase Tenecteplase

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participant must be 18 years of age or older.
2. Ingestion of FXa inhibitors within the last 48 hours of symptom onset (or ongoing prescription of FXa inhibitor if unknown)
3. Clinical diagnosis of AIS with disabling neurological deficit
4. Presenting within 4.5 h of symptom onset or after awakening with symptoms of AIS with FLAIR-DWI mismatch on MRI as judged by the (neuro-) radiologist.
5. Informed consent

Exclusion Criteria

1. Endovascular treatment eligible patients with isolated large vessel occlusion of the intracranial internal carotid artery (ICA), the M1 segment of the middle cerebral artery (MCA), or both confirmed by CT or MR angiography and expected time from randomization to groin puncture of \<30 minutes.
2. Systolic BP \>185 mmHg or diastolic BP \>110 mmHg despite antihypertensive treatment.
3. Known bleeding diathesis; manifest or recent severe bleeding; significant bleeding disorder last 6 months.
4. Arterial puncture at a non-compressible site; biopsy or lumbar puncture \<7 days; major surgery, traumatic external heart massage, obstetrical delivery or serious trauma \<14 days; history of intracranial haemorrhage; stroke \<2 months, CNS neurosurgery \<2 months; serious head trauma \<2 months; pericarditis; sepsis; bacterial endocarditis; pericarditis; acute pancreatitis; neoplasm with increased bleeding risk; any serious medical illness likely to interact with treatment (i.e. aortic dissection); confounding pre-existent neurological or psychiatric disease.
5. Any condition that, in the opinion of the treating physician, puts a patient at risk if treated with thrombolysis (i.e. signs of cerebral hemorrhage, known cerebral amyloid angiopathy, CT with signs of early ischemia greater than one-third of the middle cerebral artery territory).

Prior/Concomitant Therapy
6. Use of a) direct thrombin (II) inhibitor (Dabigatran) or b) warfarin with an INR ≥1.8; c) heparin \<48 h; d) treatment dose of LMWH \<24 h.

Prior/Concurrent Clinical Study Experience
7. Hypersensitivity to Alteplase or Tenecteplase

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No